In Vitro Influence of Specific Bacteroidales Strains on Gut and Liver Health Related to Metabolic Dysfunction-Associated Fatty Liver Disease

被引:1
作者
Garcia-Morena, Diego [1 ]
Fernandez-Cantos, Maria Victoria [1 ]
Escalera, Silvia Lopez [2 ,3 ]
Lok, Johnson [4 ]
Iannone, Valeria [4 ]
Cancellieri, Pierluca [1 ]
Maathuis, Willem [1 ]
Panagiotou, Gianni [5 ,6 ,7 ,8 ]
Aranzamendi, Carmen [9 ]
Aidy, Sahar El [9 ]
Kolehmainen, Marjukka [4 ]
El-Nezami, Hani [10 ]
Wellejus, Anja [2 ]
Kuipers, Oscar P. [1 ]
机构
[1] Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Mol Genet, Nijenborgh 7, NL-9747 AG Groningen, Netherlands
[2] Chr Hansen A S, Boge Alle 10-12, DK-2970 Horsholm, Denmark
[3] Friedrich Schiller Univ Jena, Fak Biowissensch, 18K,Bachstr, D-07743 Jena, Germany
[4] Univ Eastern Finland, Inst Publ Hlth & Clin Nutr, Sch Med, Kuopio 70200, Finland
[5] Leibniz Inst Nat Prod Res & Infect Biol Leibniz HK, Dept Microbiome Dynam, D-07745 Jena, Germany
[6] Univ Hong Kong, Dept Med, Hong Kong, Peoples R China
[7] Univ Hong Kong, State Key Lab Pharmaceut Biotechnol, Hong Kong, Peoples R China
[8] Friedrich Schiller Univ, Fac Biol Sci, D-07743 Jena, Germany
[9] Univ Groningen, Host Microbe Metab Interact, Groningen Biomol Sci & Biotechnol Inst GBB, Nijenborgh 7, NL-9747 AG Groningen, Netherlands
[10] Univ Hong Kong, Sch Biol Sci, Mol & Cell Biol Div, Pok Fu Lam, Hong Kong, Peoples R China
关键词
MAFLD; Microbiota; Bacteroidales; Antimicrobials; Fatty liver; Probiotics; MICROBIOTA; ANTIBIOTICS; EPIDEMIOLOGY; PREVALENCE; SILIBININ; SPECTRUM; OBESE; MICE;
D O I
10.1007/s12602-024-10219-1
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Metabolic dysfunction-associated fatty liver disease (MAFLD) has become a major health risk and a serious worldwide issue. MAFLD typically arises from aberrant lipid metabolism, insulin resistance, oxidative stress, and inflammation. However, subjacent causes are multifactorial. The gut has been proposed as a major factor in health and disease, and over the last decade, bacterial strains with potentially beneficial effects on the host have been identified. In vitro cell models have been commonly used as an early step before in vivo drug assessment and can confer complementary advantages in gut and liver health research. In this study, several selected strains of the order Bacteroidales were used in a three-cell line in vitro analysis (HT-29, Caco-2, and HepG2 cell lines) to investigate their potential as new-generation probiotics and microbiota therapeutics. Antimicrobial activity, a potentially useful trait, was studied, and the results showed that Bacteroidales can be a source of either wide- or narrow-spectrum antimicrobials targeting other closely related strains. Moreover, Bacteroides sp. 4_1_36 induced a significant decrease in gut permeability, as evidenced by the high TEER values in the Caco-2 monolayer assay, as well as a reduction in free fatty acid accumulation and improved fatty acid clearance in a steatosis HepG2 model. These results suggest that Bacteroidales may spearhead the next generation of probiotics to prevent or diminish MAFLD.
引用
收藏
页码:1498 / 1512
页数:15
相关论文
共 50 条
  • [21] Risk Factors for the Development of Metabolic Dysfunction-Associated Fatty Liver Disease in Mexico
    Tellez, S.
    Lopez, G.
    Gonzalez, M.
    Contreras, R.
    [J]. ANNALS OF NUTRITION AND METABOLISM, 2024, 80 : 138 - 139
  • [22] Update in lean metabolic dysfunction-associated steatotic liver disease
    Sato-Espinoza, Karina
    Chotiprasidhi, Perapa
    Huaman, Mariella R.
    Diaz-Ferrer, Javier
    [J]. WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (03) : 452 - 464
  • [23] Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-Rather a Bystander Than a Driver of Mortality
    Semmler, Georg
    Wernly, Sarah
    Bachmayer, Sebastian
    Leitner, Isabella
    Wernly, Bernhard
    Egger, Matthias
    Schwenoha, Lena
    Datz, Leonora
    Balcar, Lorenz
    Semmler, Marie
    Stickel, Felix
    Niederseer, David
    Aigner, Elmar
    Datz, Christian
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (09) : 2670 - 2677
  • [24] Acute-on-chronic liver failure in metabolic dysfunction-associated fatty liver disease patients: a disease multiplier
    Choudhury, Ashok
    Rajaram, Ruveena
    Sarin, Shiv Kumar
    [J]. HEPATOLOGY INTERNATIONAL, 2024, 18 (SUPPL 2) : 941 - 958
  • [25] Sex differences in metabolic dysfunction-associated steatotic liver disease: a narrative review
    Joo, Sae Kyung
    Kim, Won
    [J]. EWHA MEDICAL JOURNAL, 2024, 47 (02):
  • [26] Updates in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) in Children
    Rupasinghe, Kushila
    Hind, Jonathan
    Hegarty, Robert
    [J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2023, 77 (05) : 583 - 591
  • [27] Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
    Song, Byeong Geun
    Choi, Sung Chul
    Goh, Myung Ji
    Kang, Wonseok
    Sinn, Dong Hyun
    Gwak, Geum-Youn
    Paik, Yong-Han
    Choi, Moon Seok
    Lee, Joon Hyeok
    Paik, Seung Woon
    [J]. JHEP REPORTS, 2023, 5 (09)
  • [28] Metabolic dysfunction-associated fatty liver disease in people living with HIV
    Michel, Maurice
    Labenz, Christian
    Armandi, Angelo
    Kaps, Leonard
    Kremer, Wolfgang Maximilian
    Galle, Peter R.
    Grimm, Daniel
    Sprinzl, Martin
    Schattenberg, Joern M.
    [J]. SCIENTIFIC REPORTS, 2023, 13 (01)
  • [29] Menopause and metabolic dysfunction-associated steatotic liver disease
    Polyzos, Stergios A.
    Goulis, Dimitrios G.
    [J]. MATURITAS, 2024, 186
  • [30] Metabolic dysfunction-associated steatotic liver disease in children
    Goyal, Nidhi P.
    Xanthakos, Stavra
    Schwimmer, Jeffrey B.
    [J]. GUT, 2025, : 669 - 677